Trial · NCT02408523
Adverse events264
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 264
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | Placebo (SS) Treatment Period | 2 | 121 | 2 |
| other | Vertigo | Ear and labyrinth disorders | Lacosamide (SS) Treatment Period | 8 | 121 | 8 |
| other | Vertigo | Ear and labyrinth disorders | Placebo (SS) Transition Period | 3 | 108 | 4 |
| other | Vertigo | Ear and labyrinth disorders | Lacosamide (SS) Transition Period | 1 | 101 | 1 |
| other | Vertigo | Ear and labyrinth disorders | Placebo (SS) Taper Period | 0 | 7 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Lacosamide (SS) Taper Period | 0 | 9 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Placebo (SS) Safety Follow-up Period | 0 | 10 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Lacosamide (SS) Safety Follow-up Period | 0 | 11 | 0 |
| other | Nausea | Gastrointestinal disorders | Placebo (SS) Treatment Period | 7 | 121 | 7 |
| other | Nausea | Gastrointestinal disorders | Lacosamide (SS) Treatment Period | 11 | 121 | 12 |
| other | Nausea | Gastrointestinal disorders | Placebo (SS) Transition Period | 2 | 108 | 3 |
| other | Nausea | Gastrointestinal disorders | Lacosamide (SS) Transition Period | 0 | 101 | 0 |
| other | Nausea | Gastrointestinal disorders | Placebo (SS) Taper Period | 0 | 7 | 0 |
| other | Nausea | Gastrointestinal disorders | Lacosamide (SS) Taper Period | 0 | 9 | 0 |
| other | Nausea | Gastrointestinal disorders | Placebo (SS) Safety Follow-up Period | 0 | 10 | 0 |
| other | Nausea | Gastrointestinal disorders | Lacosamide (SS) Safety Follow-up Period | 0 | 11 | 0 |
| other | Vomiting | Gastrointestinal disorders | Placebo (SS) Treatment Period | 1 | 121 | 3 |
| other | Vomiting | Gastrointestinal disorders | Lacosamide (SS) Treatment Period | 7 | 121 | 10 |
| other | Vomiting | Gastrointestinal disorders | Placebo (SS) Transition Period | 3 | 108 | 5 |
| other | Vomiting | Gastrointestinal disorders | Lacosamide (SS) Transition Period | 0 | 101 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02408523/events